O. Nascimben
Impact in
-
- Breast Cancer Treatment Studies
- Reproductive Medicine top 10%
- Ovarian cancer diagnosis and treatment
Papers in
- Oncology 13
- Cancer Treatment and Pharmacology 4
- HER2/EGFR in Cancer Research 3
-
- Ovarian cancer diagnosis and treatment 4
- Co-authors
- Carlo GattiR. MioneAntonette E. LeonOrazio VinanteMassimo GionRuggero DittadiGiovanni PappagalloMaría Gión
In The Last Decade
O. Nascimben
21 papers receiving 333 citations
Peers
Comparison fields: 5 of 45
- Cancer Research 115
- Reproductive Medicine 63
- Otorhinolaryngology 28
- Oncology 173
- Radiology, Nuclear Medicine and Imaging 76
Countries citing papers authored by O. Nascimben
This map shows the geographic impact of O. Nascimben's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by O. Nascimben with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites O. Nascimben more than expected).
Fields of papers citing papers by O. Nascimben
This network shows the impact of papers produced by O. Nascimben. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by O. Nascimben. The network helps show where O. Nascimben may publish in the future.
Co-authors
The 25 scholars most cited alongside O. Nascimben, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2008 | 15 | |
| 2 | 2007 | 4 | |
| 3 | 2004 | 30 | |
| 4 | 2004 | 21 | |
| 5 | Quantitative chemiluminescent immunoassay of p53: prognostic significance in 220 node-negative breast cancer tissue. | 1998 | 4 |
| 6 | 1998 | 46 | |
| 7 | 1998 | 12 | |
| 8 | ErbB2 assay in breast cancer: possibly improved clinical information using a quantitative method. | 1997 | 28 |
| 9 | 1997 | 33 | |
| 10 | 1994 | 6 | |
| 11 | Biochemical parameters for prognostic evaluation in patients with breast cancer. | 1994 | 5 |
| 12 | 1993 | 10 | |
| 13 | 1993 | 2 | |
| 14 | 1993 | 8 | |
| 15 | 1993 | 20 | |
| 16 | 1991 | 42 | |
| 17 | 1991 | 6 | |
| 18 | 1990 | 6 | |
| 19 | 1990 | 14 | |
| 20 | 1988 | 30 |
About O. Nascimben
O. Nascimben is a scholar working on Oncology, Reproductive Medicine, Cancer Research, Otorhinolaryngology and Pulmonary and Respiratory Medicine, having authored 21 papers that have together received 352 indexed citations. Recurring topics across this work include Ovarian cancer diagnosis and treatment (4 papers), Cancer Treatment and Pharmacology (4 papers), Cancer therapeutics and mechanisms (4 papers), Breast Cancer Treatment Studies (4 papers), Glycosylation and Glycoproteins Research (3 papers), Advanced Breast Cancer Therapies (3 papers), HER2/EGFR in Cancer Research (3 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). The work is most often cited by research in Cancer Research (115 citations), Reproductive Medicine (63 citations), Otorhinolaryngology (28 citations), Oncology (173 citations) and Radiology, Nuclear Medicine and Imaging (76 citations). O. Nascimben has collaborated with scholars based in Italy, Malaysia and Nepal. Frequent co-authors include Carlo Gatti, R. Mione, Antonette E. Leon, Orazio Vinante, Massimo Gion, Ruggero Dittadi, Giovanni Pappagallo, María Gión, Giorgio Mustacchi and Salvatore Tumolo. Their work appears in journals such as European Journal of Cancer, International Journal of Radiation Oncology*Biology*Physics, Journal of Clinical Oncology, British Journal of Cancer and Breast Cancer Research and Treatment.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.